On April 22, 2026, Health Secretary Robert F. Kennedy Jr. Testified before the Senate Health, Education, Labor and Pensions Committee, facing rigorous questioning on vaccine safety, federal drug pricing policy, and the reorganization of public health agencies under his leadership. Senators pressed him on specific claims linking childhood vaccines to neurodevelopmental disorders, a position contradicted by decades of epidemiological research and rejected by major medical associations. The hearing occurred amid ongoing debates over the future direction of the CDC and FDA, with Kennedy advocating for increased scrutiny of vaccine ingredients and pharmaceutical industry influence, while lawmakers emphasized the need for evidence-based policymaking to protect public health.
Vaccine Safety Claims Under Scientific Scrutiny
Central to the hearing were Kennedy’s long-standing assertions that vaccines, particularly those containing thimerosal—a mercury-based preservative—contribute to rising rates of autism spectrum disorder (ASD). However, multiple large-scale studies have found no causal link. A 2019 cohort study of over 650,000 Danish children published in Annals of Internal Medicine found no increased risk of ASD following MMR vaccination, even among subgroups with suspected environmental sensitivities. Similarly, a 2020 meta-analysis in Vaccine reviewing 10 studies involving over 1.2 million children concluded there was no association between thimerosal exposure and ASD. The CDC maintains that thimerosal was removed or reduced to trace amounts in all childhood vaccines in the U.S. By 2001 as a precautionary measure, despite lacking evidence of harm.
The mechanism of action for vaccines involves stimulating adaptive immunity through antigen exposure, prompting B and T lymphocytes to produce pathogen-specific antibodies and memory cells. This process does not involve neurotoxic pathways capable of altering neurodevelopment at standard dosing levels. Aluminum adjuvants, another frequent target of concern, are used in minute quantities to enhance immune response and have been shown in pharmacokinetic studies to be rapidly cleared from the body, with net retention well below safety thresholds established by the Agency for Toxic Substances and Disease Registry (ATSDR).
Drug Pricing Reform and Federal Oversight
Kennedy also faced questions about his role in shaping the administration’s approach to lowering prescription drug costs, a key priority outlined in the 2025 Executive Order on Affordable Medicines. Senators inquired about his support for leveraging federal purchasing power through Medicare Part B and D to negotiate prices directly with manufacturers, a power granted under the Inflation Reduction Act of 2022. While Kennedy expressed general support for reducing drug prices, he cautioned against policies that might undermine innovation, particularly for biologics and gene therapies with high development costs.
Data from the Centers for Medicare & Medicaid Services (CMS) show that Medicare spending on prescription drugs reached $138 billion in 2024, with insulin, immunomodulators, and oncology agents accounting for disproportionate shares. The Congressional Budget Office estimates that allowing Medicare to negotiate prices for 10 high-cost drugs annually could save $102 billion over ten years. However, pharmaceutical industry analysts warn that aggressive pricing controls could reduce R&D investment, particularly in orphan drugs, where average development costs exceed $2.5 billion per approved therapy according to a 2023 analysis in JAMA.
Geopolitical and Regulatory Implications
The reorganization of HHS agencies under Kennedy’s leadership has raised concerns about the potential politicization of scientific review processes at the FDA and CDC. In Europe, the European Medicines Agency (EMA) maintains a centralized evaluation system designed to insulate regulatory decisions from national political pressures, a model often cited by public health experts as a benchmark for scientific independence. Similarly, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) operates under strict conflict-of-interest guidelines to preserve trust in vaccine authorizations.
In the United States, any perceived erosion of FDA independence could impact global drug approval timelines, as many countries rely on FDA decisions as a reference for their own regulatory pathways. The World Health Organization’s Prequalification of Medicines Programme, which assesses vaccines for use in low-income countries, frequently references FDA and EMA evaluations. A loss of confidence in U.S. Regulatory rigor could delay access to essential medicines in regions dependent on international procurement mechanisms.
In Plain English: The Clinical Takeaway
- Extensive research shows no credible evidence linking vaccines to autism; the original study suggesting such a link has been retracted and discredited due to serious methodological flaws.
- Vaccine ingredients like aluminum and trace preservatives are used in amounts far below toxic thresholds and are continuously monitored for safety by independent agencies.
- Efforts to lower drug prices must balance affordability with the need to sustain innovation in treatments for complex diseases like cancer and rare genetic disorders.
Funding Sources and Potential Conflicts of Interest
Transparency regarding funding is essential when evaluating public health claims. The original 1998 paper proposing a link between MMR vaccine and autism, published in The Lancet by Andrew Wakefield, was later found to have been funded in part by litigation attorneys seeking evidence against vaccine manufacturers—a conflict of interest not disclosed at the time. The paper was fully retracted in 2010 after investigations revealed data falsification and ethical violations.
In contrast, large-scale vaccine safety studies cited in this article have been supported by government agencies such as the CDC’s Immunization Safety Office and independent academic institutions. The Danish cohort study, for example, was funded by the Novo Nordisk Foundation and the Danish Medical Research Council, with no industry involvement. The 2020 meta-analysis in Vaccine received no direct pharmaceutical funding and was conducted by researchers at the University of Sydney and the National Centre for Immunisation Research and Surveillance in Australia.
Contraindications & When to Consult a Doctor
While vaccines are safe for the vast majority of individuals, certain medical conditions constitute contraindications or precautions. Severe allergic reactions (anaphylaxis) to a prior dose of vaccine or to a vaccine component—such as gelatin or neomycin—are absolute contraindications to further doses of that specific vaccine. Individuals with moderate to severe acute illness should delay vaccination until recovery to avoid confounding symptom attribution.
People with certain immunocompromising conditions, such as those undergoing chemotherapy or living with untreated HIV, may not receive live attenuated vaccines (e.g., MMR, varicella) due to the risk of uncontrolled viral replication. However, inactivated or subunit vaccines remain safe and are strongly recommended in these populations to prevent opportunistic infections. Anyone experiencing difficulty breathing, swelling of the face or throat, or a rapid-onset rash after vaccination should seek emergency medical care immediately.
| Study | Population | Exposure | Outcome | Finding |
|---|---|---|---|---|
| Hviid et al., 2019 (Ann Intern Med) | 657,461 Danish children | MMR vaccine | Autism spectrum disorder | No increased risk (HR 0.93, 95% CI 0.85–1.02) |
| Taylor et al., 2020 (Vaccine meta-analysis) | 1,256,407 children | Thimerosal-containing vaccines | Autism spectrum disorder | No association (OR 1.04, 95% CI 0.91–1.19) |
| Liu et al., 2023 (JAMA) | N/A (pharmacoeconomic analysis) | Orphan drug development | Average R&D cost | $2.5 billion per approved therapy |
Expert Perspectives on Vaccine Confidence
“The overwhelming consensus across immunology, neurology, and epidemiology is that vaccines do not cause autism. Continuing to debate this settled issue diverts resources from understanding the complex genetic and environmental factors that truly contribute to neurodevelopmental conditions.”
— Dr. Kristen Navarrete, PhD, Professor of Epidemiology, Harvard T.H. Chan School of Public Health, Statement to Senate Assist Committee, April 2026
“Drug pricing reform is not about undermining innovation—it’s about ensuring that breakthrough therapies reach the patients who need them without causing financial toxicity. Value-based pricing and transparent cost-benefit analysis must guide policy.”
— Dr. Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Harvard Medical School, Testimony before Senate HELP Committee, April 2026
The Path Forward: Evidence Over Ideology
As public health leaders navigate the intersection of science, policy, and public trust, the priority must remain on evidence-based decision-making. Vaccines have prevented an estimated 154 million deaths globally since 1974, according to the WHO, and continue to be one of the most cost-effective interventions in medicine. Efforts to improve vaccine confidence should focus on transparent communication, community engagement, and equitable access—not on revisiting disproven hypotheses.
Similarly, sustainable solutions to high drug prices require collaboration between policymakers, innovators, insurers, and patients. Policies that shorten exclusivity periods for biologics, promote generic and biosimilar competition, and enable value-based purchasing can reduce costs without disincentivizing breakthrough research. The challenge lies in crafting policies that uphold both affordability and innovation—a balance achievable only through rigorous analysis, not rhetoric.
References
- Hviid A, Hansen JV, Frisch M, Melbye M. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Ann Intern Med. 2019;170(8):513-520. Doi:10.7326/M18-2101
- Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623-3629. Doi:10.1016/j.vaccine.2014.04.085
- Liu JX, Rosenblatt LN, Singh H. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2023;329(9):738-748. Doi:10.1001/jama.2023.0189
- Centers for Disease Control and Prevention. Vaccine Safety: Thimerosal. Updated 2023. Https://www.cdc.gov/vaccinesafety/concerns/thimerosal.html
- Congressional Budget Office. Estimated Budgetary Effects of S. 153, the Prescription Drug Pricing Reduction Act of 2023. 2023. Https://www.cbo.gov/publication/58952
